HILLSIDE, N.J., May 7, 2025 -- HT Vista Ltd. has launched a new diagnostic function on the HT Vista screening device. The new technology enhances its unique, AI algorithm-based cancer screening tool with a diagnostic ability in cases where the specificity exceeds 90%. The update went live on March 6th 2025, with a new scoring system of low, moderate or high cancer risk, which replaces the original numerical HDI scores. This new presentation simplifies interpretation for clinicians, making the screening process easier to communicate with pet owners. HT Vista will be presenting the updated technology at BSAVA Congress, 2025 at stand C42.
Built on validated global data and utilizing ever-improving algorithms, HT Vista can now categorise cancer risk levels based on malignant probability with a sensitivity of 90% and a negative predictive value (NPV) of 98%. This translates to a "low cancer risk" result, having a malignant probability of 10% or less, allowing veterinary teams to rule out cancer of lumps and bumps without the need for invasive procedures. Furthermore, the tool can now provide alerts for some of the low-risk cases, identifying them as lipomas, sebaceus adenomas or benign epithelial masses.
Liron Levy-Hirsch DVM MRCVS, Managing Director at HT Vista, says, "I am incredibly excited to enhance our already powerful HT Vista screening tool with a new diagnostic capability, providing veterinary teams with an even more comprehensive decision-support system. Our screening technology has already been a game-changer in early detection, and now, with the ability to flag specific tumor types, we are taking another significant step forward. This advancement empowers veterinary professionals to make even more informed decisions, supports shared decision-making with pet owners, and ultimately improves patient outcomes. By reducing the time from suspicion to diagnosis and treatment, we can detect cancer earlier, avoid the 'wait and see' approach, and help save more lives."
On the other end of the scale, a "high cancer risk" result has a malignant probability of 50% or more and indicates a stronger likelihood of malignancy. These cases require additional diagnostic tests for mass identification. Additionally, for some of the high-risk cases, HT Vista can identify specific malignant masses like mast cell tumors. A "moderate cancer risk", with malignant probability of 10%-50%, suggests further investigation is recommended, and advises against monitoring over time.
The new update further strengthens HT Vista's position in bridging the gap between screening and diagnosis. It removes the need for the "wait and see" approach, with a quick and painless procedure that appeals to pet owners. A key distinction from other screening modalities is that it can be nurse-led. In a time of economic tightening, the HT Vista is an efficient, cost-effective path to a diagnosis.
Dr Anish Patel, Veterinarian and Clinic Owner of Max & Min Veterinary Clinic who has the device installed, commented that, "The HT Vista has transformed the way we now investigate lumps in dogs. We now use the device to screen every cutaneous or subcutaneous lump that we see in our canine patients prior to obtaining an aspirate. We have seen the greatest impact in patients with multiple, long-standing skin masses where owners can be reluctant to aspirate or biopsy multiple lesions and are more concerned about the risk of GA or sedation. The non-invasive nature of the HT Vista is much more appealing to pet owners and gives a quick result within minutes! In addition, the algorithm and AI are constantly evolving and learning from the samples that are taken and so I am confident the scanner will become even more accurate in the future!"
More information on HT Vista's new screening and diagnostic capabilities can be found on this blog: https://bit.ly/ht-vista-screening-tool
About HTVista
HT Vista is the UK subsidiary of HT VET, an Israeli based company aiming to increase early cancer detection of lumps and bumps cancer in dogs. Its revolutionary patented medical imaging technology, Heat Diffusion Imaging, was developed by a team of experts in the fields of AI, signal analysis and computer vision, together with top researchers in heat transfer and thermodynamics, oncologists and radiologists.
The HT Vista device is used in the US, UK, Germany, Sweden, Norway, Switzerland, Greece, Italy, The Netherlands, Australia and Israel. It's first subsidiary is in the UK with Liron Levy-Hirsch as Managing Director. For more information contact liron@htbioimaging.com or visit www.ht-vet.com
Press Contact
Shahni Ben-Haim
shahni@sbhmedia.com
This News is brought to you by Qube Mark, your trusted source for the latest updates and insights in marketing technology. Stay tuned for more groundbreaking innovations in the world of technology.
